Therapeutic Areas
Advancing Health Through Science and Strategic Partnerships
Our journey began in 2013 under the name TRPharm, and in 2025, we continue as Inpharmus, in line with our vision of becoming a global healthcare company.
Contact UsRare Diseases
Although each rare disease affects only a small number of individuals, together they impact millions worldwide. Today, over 6,000 rare disorders have been identified, and this number continues to grow as advances in diagnostics reveal new conditions. While individually uncommon, rare diseases collectively represent a significant public health challenge.
The definition of “rare” can vary across regions. A disorder considered rare in one geography may be more prevalent in another due to founder mutations, genetic background, environmental factors, or increased clinical awareness.
Clinical Overview
Rare diseases often arise from genetic, immunological, metabolic, or neuroinflammatory mechanisms. While many are genetic, some result from immune dysregulation, autoinflammatory pathways, or complex metabolic processes.
Patients frequently experience a prolonged “diagnostic odyssey,” lasting several years. Limited disease awareness, fragmented care pathways, and insufficient access to specialized centers contribute to these delays. Beyond medical concerns, rare diseases impose significant psychological, social, and economic burdens on patients and their families.
Inpharmus Mission in Rare Diseases
Guided by scientific insights into neurological, immunological, and metabolic mechanisms, Inpharmus works to support earlier diagnosis, strengthen access to treatments, and ensure the delivery of effective therapies.
Inpharmus Focus Areas
We partner with physicians and pharmacists to advance care in rare neurological, metabolic, autoinflammatory, and immune-mediated disorders, each affecting fewer than 1 in 50,000 individuals. Our approach integrates:
✦ Support for early and accurate diagnosis
✦ Evidence-based therapeutic strategies
✦ Collaboration with specialized centers
✦ Scientific education and awareness initiatives
✦ Continuous partnership with healthcare professionals
Important Notice
All content on this website is intended exclusively for physicians and pharmacists for informational and educational purposes. The information provided does not replace medical advice. Diagnosis and treatment decisions must be made solely by qualified healthcare professionals.
Hematology
The hematologic system plays a central role in oxygen transport, immune defense, coagulation, and cellular homeostasis. Disorders can result from defects in blood cell production, proliferation, or differentiation, or from immune dysregulation. The clinical spectrum ranges from acquired conditions to genetically driven syndromes that require advanced, multidisciplinary care.
Modern hematology increasingly focuses on:
✦ Immune-mediated cytopenias
✦ Bone marrow failure syndromes
✦ Disorders of inflammation and uncontrolled immune activation
✦ Genetic predispositions affecting hematopoietic lineages
Hemophagocytic and hyperinflammatory presentations
Many of these conditions progress rapidly and can become life-threatening. Early recognition, thorough immunological assessment, and timely therapeutic intervention are essential for patient survival. Research highlights the critical role of cytokine dysregulation, genetic susceptibility, and immune overactivation in the development of select hematologic disorders.
Inpharmus Mission in Hematology
Inpharmus partners with healthcare professionals to support the management of complex hematologic conditions through scientific collaboration and evidence-based approaches. We aim to enhance diagnostic accuracy, deepen understanding of immune and cellular mechanisms, and improve access to innovative therapies for patients facing challenging hematologic diseases.
Important Notice
All content on this website is intended exclusively for physicians and pharmacists forinformational and educational purposes. The information provided does not replace medical advice. Diagnosis and treatment decisionsmust be made by qualified healthcare professionals.
Oncology
The human body relies on a highly regulated system that governs cell growth, maturation, proliferation, and programmed cell death (apoptosis) from the earliest stages of development. Cancer arises when these regulatory mechanisms are disrupted by accumulated genetic, epigenetic, or molecular alterations, resulting in the uncontrolled expansion of abnormal cells.
Malignancies can originate in nearly any tissue or organ. Even within the same anatomical site, distinct cancer subtypes may emerge depending on genetic drivers, signaling pathways, and characteristics of the tumor microenvironment. Despite this biological diversity, all cancers share a fundamental hallmark: dysregulated and uncontrolled cell division.
Current focus areas in contemporary oncology include:
✦ Fundamental tumor biology and signaling mechanisms
✦ Pediatric solid tumors and rare malignancies
✦ Treatment-related toxicities and organ protection strategies
✦ Immune-mediated and targeted therapeutic approaches
✦ Disease progression, evolutionary dynamics, and resistance mechanisms
Inpharmus collaborates with oncology specialists to enhance scientific understanding, strengthen diagnostic pathways, and support evidence-based clinical decision making. Through rigorous ethical and regulatory adherence, the company contributes to broader access to innovative therapeutic strategies and advances awareness of the complex biological mechanisms underlying challenging cancer types.
Important Notice
All content on this website is intended exclusively for physicians and pharmacists forinformational and educational purposes. The information provided does not replace medical advice. Diagnosis and treatment decisionsmust be made solely by qualified healthcare professionals.